FDA grants accelerated approval for Bristol Myers Squibb’s Augtyro for NTRK-positive tumors

Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene ... Read More